Skip to main content

Table 4 Spirometry outcomes in tiotropium and placebo groups according to different threshold criteria for bronchodilator responsiveness.

From: Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

A Criterion A (∆ % Predicted FEV1≥12% and ≥200 mL) Criterion B (∆ % Predicted FEV1≥15%) Criterion C (∆ % Predicted FEV1≥10%)
  Nonresponder Responder Nonresponder Responder Nonresponder Responder
Prebronchodilator             
   Difference in FEV1 at 4 years (mL)* 76 (54, 98) 98 (77, 119) 97 (69, 124) 83 (65, 101) 78 (58, 97) 105 (81, 130)
   Difference in FVC at 4 years (mL)* 134 (89, 178) 195 (153, 236) 143 (92, 194) 179 (140, 217) 139 (99, 179) 213 (165, 260)
B Criterion A (∆ % Predicted FEV 1 ≥12% and ≥200 mL) Criterion B (∆ % Predicted FEV 1 ≥15%) Criterion C (∆ % Predicted FEV 1 ≥10%)
  Nonresponder Responder Nonresponder Responder Nonresponder Responder
  Tio Placebo Tio Placebo Tio Placebo Tio Placebo Tio Placebo Tio Placebo
Rate of change in FEV1 (mL/year)             
   Prebronchodilator -32 ± 2 -31 ± 2 -29 ± 2 -29 ± 2 -35 ± 2 -38 ± 2 -28 ± 2 -26 ± 2 -32 ± 2 -32 ± 2 -28 ± 2 -28 ± 2
   Postbronchodilator -37 ± 2 -37 ± 2 -43 ± 2 -47 ± 2 -38 ± 2 -42 ± 2 -42 ± 2 -43 ± 2 -39 ± 2 -39 ± 2 -43 ± 2 -47 ± 2
  1. (A) mean differences (95%CI) at 4 years (tiotropium - placebo), (B) mean (SE) rate of change by treatment group.
  2. In patients with at least three measurements after Day 30. Change in FEV1 and FVC data are based on repeated-measures ANOVA model, adjusted for baseline. Rates of decline in FEV1 data are based on random-effects model.
  3. *p ≤ 0.001 versus placebo. Tio = tiotropium; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity.
\